Turn Therapeutics
Turn Therapeutics is a clinical-stage biotechnology company developing targeted, localized, non-systemic therapies for inflammatory and infectious skin diseases. Its lead program, GX-03, is a topical IL-36/IL-31 pathway inhibitor in Phase 2 for moderate-to-severe atopic dermatitis; a July 2026 interim analysis supported expanding Stage 2 enrollment to roughly 120-135 patients, with topline data targeted for Q4 2026 and a Phase 2a study in hidradenitis suppurativa planned. The company's PermaFusion formulation platform is being developed with Medline under a global supply, development and license agreement, and supports a thermostable intranasal vaccine initiative. Turn Therapeutics (formerly Global Health Solutions, renamed in September 2025) completed a direct listing on Nasdaq in October 2025 and named former FDA Commissioner Stephen M. Hahn as Executive Clinical and Regulatory Lead in May 2026.
Company Info
Upcoming Milestones & Key Dates
GX-03 Phase 2 atopic dermatitis topline readout
Clinical Development Pipeline
GX-03 (topical IL-36/IL-31 pathway inhibitor)
Target: Localized, non-systemic inhibition of IL-36/IL-31 inflammatory signalingGX-03 (topical IL-36/IL-31 pathway inhibitor)
Target: Localized, non-systemic inhibition of IL-36/IL-31 inflammatory signalingPermaFusion intranasal vaccine candidate
Target: Thermostable, lipid-enveloped intranasal vaccine formulationRecent News
No recent news updates available for this company.
Leadership Team
Bradley Burnam
Founder and Chief Executive Officer
Stephen M. Hahn, M.D.
Executive Clinical and Regulatory Lead (former FDA Commissioner)
Careers & Job Openings
No active job listings. Check back later.